{"commentary":{"count":147,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":83,"podcast":31,"youtube":30,"x_video":3},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05132582\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"HER2CLIMB-05","nct_id":"NCT05132582","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=her2climb-05-nct05132582. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"HER2CLIMB-05","arms":[{"description":"Tucatinib + trastuzumab + pertuzumab","label":"Tucatinib + trastuzumab + pertuzumab","type":"EXPERIMENTAL"},{"description":"Placebo + trastuzumab + pertuzumab","label":"Placebo + trastuzumab + pertuzumab","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2027-09-28","type":"ESTIMATED"},"conditions":["HER2 Positive Breast Cancer"],"enrollment":{"count":654,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Tucatinib","type":"DRUG"},{"name":"Trastuzumab","type":"DRUG"},{"name":"Pertuzumab","type":"DRUG"},{"name":"Combination product: Trastuzumab + Pertuzumab","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"last_update":"2026-09-29","lead_sponsor":"Seagen, a wholly owned subsidiary of Pfizer","official_title":"A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2025-09-05","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-Free Survival (PFS) as Assessed by Investigator Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1","timeFrame":"From randomization until the first documentation of PD or death from any cause or censoring date, whichever occurred first (maximum treatment exposure was of 41.3 months)"}],"references":[{"citation":"Dieras V, Curigliano G, Martin M, Lerebours F, Tsurutani J, Savard MF, Jerzak KJ, Hu X, Martins de Aquino Pimentel LC, O'Sullivan CC, Tokunaga E, Okines A, Huang CS, Jacot W, Sohn J, Cronemberger Silva E, Mueller V, Yang S, Granata G, Shen Q, Santarpia L, Hamilton E; HER2CLIMB-05 Investigators. HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer. J Clin Oncol. 2026 Jun 10;44(17):1597-1607. doi: 10.1200/JCO-25-02600. Epub 2025 Dec 10.","pmid":"41369677","type":"DERIVED"}],"start_date":{"date":"2022-03-07","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer","url":"https://clinicaltrials.gov/study/NCT05132582"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/her2climb-05-nct05132582"}